報價延遲最少15分鐘:2025/06/03 19:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.77/-0.85
|
|
企業價值
146.72M
|
| 資產負債 |
|
每股賬面淨值
-0.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.11
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 19:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal sprayto be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |